NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Babak Alex Vakili: Net Clinical Benefit Favors OAC Alone, According to the AQUATIC Trial
Babak Alex Vakili/LinkedIn
Nov 7, 2025, 01:34

Babak Alex Vakili: Net Clinical Benefit Favors OAC Alone, According to the AQUATIC Trial

Babak Alex Vakili, President and CEO at Heart Vein and Vascular Clinic, shared on LinkedIn:

”For Atrial Fibrillation patients with CAD, who are > 6 months post PCI and who are on OAC (Eliquis, Xarelto) and Aspirin combination, stop aspirin unless strongly indicated (eg recent ACS or stent thrombosis). Net clinical benefit favors OAC alone, according the Aquatic Trial.

NEJM AQUATIC Trial (Oct 23 2025)

  • Published in The New England Journal of Medicine
  • Title: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation

In this double-blind, multicenter French RCT (N = 872), patients with prior PCI and high atherothrombotic risk—all on long-term oral anticoagulation (OAC)—were randomized to OAC + aspirin 100 mg daily vs OAC + placebo.
After a median 2.2 years, the trial was stopped early due to excess deaths in the aspirin arm.

Results:

  • Primary composite (CV death, MI, stroke, embolism, revasc, acute limb ischemia): 16.9 % with aspirin vs 12.1 % placebo → HR 1.53 (P = 0.02)
  • All-cause death: 13.4 % vs 8.4 % → HR 1.72 (P = 0.01)
  • Major bleeding (ISTH): 10.2 % vs 3.4 % → HR 3.35 (P < 0.001)

Oral anticoagulants used:
Apixaban ~60–62 %, Rivaroxaban ~25 %, Dabigatran ~3–5 %, Warfarin ~10 % (≈ 90 % DOACs overall).

Top 5 Takeaways:

  1. In CCS patients >6–12 mo post-PCI on OAC, adding aspirin increases ischemic events and bleeding without benefit.
  2. All-cause mortality was significantly higher with OAC + ASA.
  3. Major bleeding tripled with dual therapy.
  4. Apixaban was the most common OAC, mirroring real-world practice.
  5. OAC monotherapy should be the default after the initial post-PCI period unless clear indication for ASA exists.”

Article: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation

Authors: Gilles Lemesle, Romain Didier, Philippe Gabriel Steg, Tabassome Simon, Gilles Montalescot, Nicolas Danchin, Christophe Bauters, Didier Blanchard, Claire Bouleti, Denis Angoulvant, Stéphane Andrieu, Gérald Vanzetto, Mathieu Kerneis, Véronique Decalf, Etienne Puymirat, Dominique Mottier, Abdourahmane Diallo, Eric Vicaut, Martine Gilard, Guillaume Cayla

Babak Alex Vakili

Read full articcle here.

Stay updated on all scientific advances with Hemostasis Today.

Abdourahmane Diallo Anticoagulation AQUATIC Trial Aspirin Atrial Fibrillation Babak Alex Vakili bleeding Cardiology Christophe Bauters Claire Bouleti Denis Angoulvant Didier Blanchard Dominique Mottier Embolism Eric Vicaut Etienne Puymirat Gérald Vanzetto Gilles Lemesle Gilles Montalescot Guillaume Cayla Health Hematology Hemostasis Today Martine Gilard Mathieu Kerneis Medicine MI NEJM Nicolas Danchin Philippe Gabriel Steg Romain Didier Stéphane Andrieu stroke Tabassome Simon thrombosis Véronique Decalf
NewsFeed